Mitapivat
Hemolytic Anemia
National Heart, Lung, and Blood Institute (NHLBI)Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hemolytic Anemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TETRACOSACTIDE University of Virginia | Phase 3 | BB |
Ribavirin National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | BB |
Deferasirox Novartis Pharmaceuticals | Phase 2 | B |
DESFERRIOXAMINE B Novartis Pharmaceuticals | Phase 2 | B |
Sodium Nitrite National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 | CC |
Same molecule, other indications
Mitapivat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →